Compelo Medical Devices - Latest industry news and analysis is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More

Hypertension Diagnostics Reports 234% Increase In Q2 Revenues

Hypertension Diagnostics has reported a revenue of $458,325 for the second quarter (Q2) of fiscal year 2010 which ended December 31, 2009, an increase of 234% compared to Q2 2009 that ended December 31, 2008.

Q2 revenue from the sale of the company’s research product used in the Start sub-study on Arterial Elasticity that is examining blood vessel function and cardiovascular risk during HIV infection and funded by the National Institutes of Health (NIH) was $106,340. As December 31, 2009, 13 of the 15 total Start units have been shipped; therefore Hypertension Diagnostics does not expect any material recurring revenue from Start.

Q2 revenue from non-Start sources was $351,985, a 157% increase from the prior year’s second quarter total revenue and a 73% increase from Q1 2010’s non-Start revenue of $203,330. Total revenue for Q2 2010 increased 52% from total revenue for Q1 2010 of $302,076.

The net loss for Q2 2010 was $233,129, compared to a net loss of $191,165 for Q2 2009. Total non-cash charges (deferred compensation, depreciation, stock options expense) of $328,817 are included in the net loss for Q2 2010.

In Q2 2009, total non-cash charges were $92,178. Excluding deferred compensation expense, which is largely influenced by changes in the company’s stock price, it generated non-GAAP pro-forma net income of $126,495 for Q2.

Mark Schwartz, chairman and CEO, said: “We are pleased by the magnitude of our second quarter sales growth. For the first half of fiscal year 2010, HDI has generated 150% of the revenue generated for the entire fiscal year 2009. We are on track to have one of our best years in recent memory.”